The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Sainsbury's Gets More Downgrades

Fri, 22nd Feb 2019 09:37

LONDON (Alliance News) - The following London-listed shares received analyst recommendations on Thursday and on Friday morning:----------FTSE 100----------UBS CUTS J SAINSBURY TO 'NEUTRAL' ('BUY') - TARGET 245 (435) PENCE----------KEPLER CHEUVREUX CUTS J SAINSBURY TO 'HOLD' ('BUY') - TARGET 221 (337) PENCE----------KEPLER CHEUVREUX CUTS INTERTEK TO 'HOLD' ('BUY') - TARGET 5150 (5045) PENCE----------CREDIT SUISSE CUTS HSBC PRICE TARGET TO 655 (695) PENCE - 'NEUTRAL' ----------GOLDMAN CUTS STANDARD CHARTERED PRICE TARGET TO 910 (930) PENCE - 'CONVICTION BUY LIST'----------CFRA CUTS BARCLAYS PRICE TARGET TO 2100 (2200) PENCE - 'STRONG BUY'----------DEUTSCHE BANK RAISES BARCLAYS PRICE TARGET TO 216 (207) PENCE - 'BUY'----------DZ BANK CUTS BAE SYSTEMS FAIR VALUE TO 550 (560) PENCE - 'BUY'----------JPMORGAN CUTS BAE SYSTEMS PRICE TARGET TO 530 (545) PENCE - 'NEUTRAL'----------CREDIT SUISSE CUTS BAE SYSTEMS PRICE TARGET TO 600 (635) PENCE - 'OUTPERFORM'----------RBC RAISES SEGRO PRICE TARGET TO 650 (625) PENCE - 'SECTOR PERFORM'----------CFRA CUTS GLENCORE TO 'HOLD' (BUY) - PRICE TARGET 330 (340) PENCE----------JPMORGAN RAISES ANGLO AMERICAN PRICE TARGET TO 2290 (2270) PENCE - 'OVERWEIGHT'----------Barclays Raises Anglo American Price Target To 2,000p From 1,800, Hold ----------DEUTSCHE BANK RAISES ANGLO AMERICAN PRICE TARGET TO 2000 (1800) PENCE - 'HOLD'----------CFRA RAISES ANGLO AMERICAN PRICE TARGET TO 2200 (2000) PENCE - 'BUY'----------GOLDMAN CUTS CENTRICA TO 'NEUTRAL' ('BUY') - TARGET 132 (158) PENCE----------GOLDMAN RAISES FRESNILLO PRICE TARGET TO 1300 (1125) PENCE - 'CONVICTION BUY LIST'----------UBS CUTS GLAXOSMITHKLINE TO 'NEUTRAL' (BUY) - PRICE TARGET 1650 (1700) PENCE----------CFRA RAISES RELX PRICE TARGET TO 1770 (1700) PENCE - 'HOLD'----------FTSE 250----------CFRA RAISES SERCO GROUP TO 'HOLD' ('SELL') - TARGET 130 (85) PENCE----------JPMORGAN RAISES GO-AHEAD GROUP TARGET TO 1519 (1466) PENCE - 'UNDERWEIGHT'----------JPMORGAN CUTS KAZ MINERALS PRICE TARGET TO 530 (550) PENCE - 'NEUTRAL'----------GOLDMAN RAISES CENTAMIN PRICE TARGET TO 130 (115) PENCE - 'NEUTRAL'----------HSBC RAISES GREENE KING PRICE TARGET TO 655 (560) PENCE - 'HOLD'----------HSBC RAISES JD WETHERSPOON PRICE TARGET TO 1475 (1310) PENCE - 'BUY'----------BERENBERG CUTS INTU PROPERTIES PRICE TARGET TO 130 (150) PENCE - 'HOLD'----------Peel Hunt Downgrades Bank of Georgia To Add From Buy, price target 1,900p from 2,250p----------Peel Hunt Cuts OneSavings Bank Price Target To 460p From 520p, Buy ----------Peel Hunt Cuts Provident Financial Price Target To 550p From 680p - Hold ----------Peel Hunt Cuts TBC Bank Price Target To 2,015p From 2,285p - Buy ----------OTHER MAIN MARKET AND AIM----------Peel Hunt Cuts Non-Standard Finance To Reduce From Hold, Price Target To 52p From 70p----------Peel Hunt Cuts Charter Court Financial Services Price Target To 340p From 370p - Buy ----------Peel Hunt Cuts Arrow Global Price Target To 200p From 265p, Hold ----------RBC CUTS GOCOMPARE PRICE TARGET TO 125 (135) PENCE - 'OUTPERFORM'----------BERENBERG CUTS SUMO GROUP PRICE TARGET TO 170 (205) PENCE - 'BUY'----------GOLDMAN RAISES LONMIN PRICE TARGET TO 75 (50) PENCE - 'NEUTRAL'----------GOLDMAN CUTS PETRA DIAMONDS PRICE TARGET TO 30 (41) PENCE - 'NEUTRAL'----------BERENBERG CUTS MCBRIDE PRICE TARGET TO 95 (140) PENCE - 'HOLD'----------PEEL HUNT RAISES FUTURE PRICE TARGET TO 750 (660) PENCE - 'BUY'----------Peel Hunt Cuts Secure Trust Bank To Sell From Reduce, Price Target 1,100p ----------

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.